Blood-based diagnosis of pediatric tuberculosis: A prospective cohort study in South Africa and Dominican Republic
- PMID: 39755278
- PMCID: PMC11830550
- DOI: 10.1016/j.jinf.2024.106404
Blood-based diagnosis of pediatric tuberculosis: A prospective cohort study in South Africa and Dominican Republic
Abstract
Objectives: Pediatric tuberculosis (TB) diagnosis is complicated by challenges in obtaining invasive respiratory specimens that frequently contain few Mycobacterium tuberculosis (Mtb) bacilli. We report the diagnostic performance of an Mtb antigen-derived peptide (MAP-TB) assay and its ability to monitor TB treatment response.
Methods: Study cohorts enrolled children who presented with presumptive TB at two hospitals in South Africa from 2012 to 2017 (157 children aged <13 years) and at community-based clinics in the Dominican Republic from 2019 to 2023 (101 children aged <18 years). Children were evaluated for TB at enrollment and six months post-enrollment and assigned confirmed, unconfirmed, or unlikely TB diagnoses using the 2015 NIH diagnostic criteria for pediatric TB. MAP-TB assay performance was evaluated using serum collected at baseline and at regular intervals post-enrollment following STARD guidelines.
Results: MAP-TB sensitivity for confirmed and unconfirmed TB was comparable to culture and Xpert sensitivity for confirmed TB, but MAP-TB specificity revealed age-dependence, decreasing from 98·1% to 78·4%, when including children aged <1 year. MAP-TB values decreased by six months post-treatment initiation in children with symptom improvement.
Conclusions: Serum MAP-TB results can effectively diagnose pediatric TB, including unconfirmed and extrapulmonary TB missed by current methods, and correspond to effective treatment.
Keywords: Extrapulmonary tuberculosis; Immuno-affinity liquid chromatography-tandem mass spectrometry; Mycobacterium tuberculosis antigen-derived peptide; Non-sputum diagnostics; Paucibacillary tuberculosis; Pediatric tuberculosis.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TYH Patent Number PCT US20/37785; founder of NanoPin Technologies; owns stock in NanoPin Technologies. CJL, officer at NanoPin Technologies; inventor on NanoPin Patent Application Number: 63/006.822; owns stock in NanoPin Technologies.
References
-
- WHO Global Tuberculosis Programme. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Available from: https://www.who.int/publications/i/item/9789240083851.
-
- Reuter A, Hughes J, Furin J. Challenges and controversies in childhood tuberculosis. Lancet 2019;394(10202):967–78. - PubMed
-
- Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med 2012;367(4):348–61. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical